Novocure's lung cancer device slows progression to brain in trial, shares rise

Novocure (NVCR.O) said on Wednesday that its device met the main goal of a late-stage trial by slowing the progression of cancer to the brain in patients with a type of lung cancer, sending its shares up about 33% in before-the-bell trading.